Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor.

Giotis ES, Carnell G, Young EF, Ghanny S, Soteropoulos P, Wang LF, Barclay WS, Skinner MA, Temperton N.

Nat Microbiol. 2019 Jul 29. doi: 10.1038/s41564-019-0517-3. [Epub ahead of print]

PMID:
31358984
2.

Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry.

Mazzon M, Ortega-Prieto AM, Imrie D, Luft C, Hess L, Czieso S, Grove J, Skelton JK, Farleigh L, Bugert JJ, Wright E, Temperton N, Angell R, Oxenford S, Jacobs M, Ketteler R, Dorner M, Marsh M.

Viruses. 2019 Feb 20;11(2). pii: E176. doi: 10.3390/v11020176.

3.

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Dong W, Bhide Y, Sicca F, Meijerhof T, Guilfoyle K, Engelhardt OG, Boon L, de Haan CAM, Carnell G, Temperton N, de Vries-Idema J, Kelvin D, Huckriede A.

Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018.

4.

A naturally protective epitope of limited variability as an influenza vaccine target.

Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S.

Nat Commun. 2018 Sep 21;9(1):3859. doi: 10.1038/s41467-018-06228-8.

5.

Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.

Gallinaro A, Borghi M, Bona R, Grasso F, Calzoletti L, Palladino L, Cecchetti S, Vescio MF, Macchia D, Morante V, Canitano A, Temperton N, Castrucci MR, Salvatore M, Michelini Z, Cara A, Negri D.

Front Immunol. 2018 Feb 5;9:171. doi: 10.3389/fimmu.2018.00171. eCollection 2018.

6.

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis.

Ferrara F, Temperton N.

Methods Protoc. 2018 Jan 22;1(1). pii: E8. doi: 10.3390/mps1010008.

7.

The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays.

Ferrara F, Molesti E, Scott S, Cattoli G, Temperton N.

Pathogens. 2017 Sep 25;6(4). pii: E45. doi: 10.3390/pathogens6040045.

8.

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.

Tully CM, Chinnakannan S, Mullarkey CE, Ulaszewska M, Ferrara F, Temperton N, Gilbert SC, Lambe T.

J Immunol. 2017 Jul 19. pii: ji1600939. doi: 10.4049/jimmunol.1600939. [Epub ahead of print]

PMID:
28724579
9.

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC.

Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.

10.

Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014.

Marchi S, Trombetta CM, Gasparini R, Temperton N, Montomoli E.

J Prev Med Hyg. 2017 Mar;58(1):E27-E33.

11.

Chimeric influenza haemagglutinins: Generation and use in pseudotype neutralization assays.

Ferrara F, Temperton N.

MethodsX. 2016 Dec 15;4:11-24. doi: 10.1016/j.mex.2016.12.001. eCollection 2017.

12.

The Optimisation of Pseudotyped Viruses for the Characterisation of Immune Responses to Equine Influenza Virus.

Scott SD, Kinsley R, Temperton N, Daly JM.

Pathogens. 2016 Dec 15;5(4). pii: E68.

13.

Stalking influenza by vaccination with pre-fusion headless HA mini-stem.

Valkenburg SA, Mallajosyula VV, Li OT, Chin AW, Carnell G, Temperton N, Varadarajan R, Poon LL.

Sci Rep. 2016 Mar 7;6:22666. doi: 10.1038/srep22666.

14.

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.

Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC, Zhang Q.

Vaccine. 2016 Mar 29;34(14):1688-95. doi: 10.1016/j.vaccine.2016.02.028. Epub 2016 Feb 20.

PMID:
26902548
15.

Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.

Vrdoljak A, Allen EA, Ferrara F, Temperton NJ, Crean AM, Moore AC.

J Control Release. 2016 Mar 10;225:192-204. doi: 10.1016/j.jconrel.2016.01.019. Epub 2016 Jan 14.

PMID:
26774221
16.

An optimised method for the production of MERS-CoV spike expressing viral pseudotypes.

Grehan K, Ferrara F, Temperton N.

MethodsX. 2015 Oct 13;2:379-84. doi: 10.1016/j.mex.2015.09.003. eCollection 2015.

17.

Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody.

Xiong X, Corti D, Liu J, Pinna D, Foglierini M, Calder LJ, Martin SR, Lin YP, Walker PA, Collins PJ, Monne I, Suguitan AL Jr, Santos C, Temperton NJ, Subbarao K, Lanzavecchia A, Gamblin SJ, Skehel JJ.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9430-5. doi: 10.1073/pnas.1510816112. Epub 2015 Jul 13.

18.

Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype.

Mallajosyula VV, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA, Varadarajan R.

Front Immunol. 2015 Jun 26;6:329. doi: 10.3389/fimmu.2015.00329. eCollection 2015.

19.

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.

Long J, Wright E, Molesti E, Temperton N, Barclay W.

Version 2. F1000Res. 2015 Jan 29 [revised 2015 Jan 1];4:30. doi: 10.12688/f1000research.6085.2. eCollection 2015.

20.

Pseudotype-based neutralization assays for influenza: a systematic analysis.

Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ.

Front Immunol. 2015 Apr 29;6:161. doi: 10.3389/fimmu.2015.00161. eCollection 2015. Review.

21.

The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination.

Bentley EM, Mather ST, Temperton NJ.

Vaccine. 2015 Jun 12;33(26):2955-62. doi: 10.1016/j.vaccine.2015.04.071. Epub 2015 Apr 30.

PMID:
25936665
22.

Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses.

Benfield CT, Smith SE, Wright E, Wash RS, Ferrara F, Temperton NJ, Kellam P.

J Gen Virol. 2015 May;96(Pt 5):991-1005. doi: 10.1099/vir.0.000058. Epub 2015 Jan 22.

23.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13.

PMID:
25513756
24.

Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A.

J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.

25.

Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit.

Mather ST, Wright E, Scott SD, Temperton NJ.

J Virol Methods. 2014 Dec 15;210:51-8. doi: 10.1016/j.jviromet.2014.09.021. Epub 2014 Oct 5.

PMID:
25286181
26.

Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies.

Molesti E, Wright E, Terregino C, Rahman R, Cattoli G, Temperton NJ.

J Immunol Res. 2014;2014:457932. doi: 10.1155/2014/457932. Epub 2014 Jul 3.

27.

Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals.

Molesti E, Ferrara F, Lapini G, Montomoli E, Temperton N.

Biomed Res Int. 2014;2014:231365. doi: 10.1155/2014/231365. Epub 2014 Jun 11.

28.

Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection.

Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, Varadarajan R.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2514-23. doi: 10.1073/pnas.1402766111. Epub 2014 Jun 9.

29.

Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests.

Wallerström S, Lagerqvist N, Temperton NJ, Cassmer M, Moreno A, Karlsson M, Leijon M, Lundkvist A, Falk KI.

Infect Ecol Epidemiol. 2014 Jan 15;4. doi: 10.3402/iee.v4.23011. eCollection 2014 Jan 15.

30.

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E.

Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707. Review.

31.

Comparative serological assays for the study of h5 and h7 avian influenza viruses.

Molesti E, Milani A, Terregino C, Cattoli G, Temperton NJ.

Influenza Res Treat. 2013;2013:286158. doi: 10.1155/2013/286158. Epub 2013 Sep 15.

32.

Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro.

Smith SE, Gibson MS, Wash RS, Ferrara F, Wright E, Temperton N, Kellam P, Fife M.

J Virol. 2013 Dec;87(23):12957-66. doi: 10.1128/JVI.01443-13. Epub 2013 Sep 25.

33.

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Mullarkey CE, Boyd A, van Laarhoven A, Lefevre EA, Veronica Carr B, Baratelli M, Molesti E, Temperton NJ, Butter C, Charleston B, Lambe T, Gilbert SC.

Eur J Immunol. 2013 Jul;43(7):1940-52. doi: 10.1002/eji.201242922. Epub 2013 Jun 10.

34.
35.

Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses.

Mahallawi WH, Kasbekar AV, McCormick MS, Hoschler K, Temperton N, Leong SC, Beer H, Ferrara F, McNamara PS, Zhang Q.

J Virol. 2013 May;87(10):5331-9. doi: 10.1128/JVI.03547-12. Epub 2013 Mar 6.

36.

The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses.

Molesti E, Cattoli G, Ferrara F, Böttcher-Friebertshäuser E, Terregino C, Temperton N.

J Mol Genet Med. 2012;7:315-20. Epub 2013 Feb 19.

37.

The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.

Ferrara F, Molesti E, Böttcher-Friebertshäuser E, Cattoli G, Corti D, Scott SD, Temperton NJ.

J Mol Genet Med. 2012;7:309-14. Epub 2013 Feb 20.

38.

The use of equine influenza pseudotypes for serological screening.

Scott S, Molesti E, Temperton N, Ferrara F, Böttcher-Friebertshäuser E, Daly J.

J Mol Genet Med. 2012;6:304-8. Epub 2012 Dec 31.

39.

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A.

Science. 2011 Aug 12;333(6044):850-6. doi: 10.1126/science.1205669. Epub 2011 Jul 28.

40.

Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus.

Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, Molesti E, Aly MM, Arafa A, Capua I.

J Virol. 2011 Sep;85(17):8718-24. doi: 10.1128/JVI.02403-10. Epub 2011 Jul 6.

41.

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ.

PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665.

42.

Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection.

Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X.

J Infect Dis. 2011 Apr 15;203(8):1063-72. doi: 10.1093/infdis/jiq168.

PMID:
21450996
43.

Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines.

Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, Molesti E, Temperton NJ, Barclay WS, Jones IM.

J Virol. 2011 Mar;85(6):3010-4. doi: 10.1128/JVI.01241-10. Epub 2010 Dec 29.

44.

Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses.

Wright E, Hayman DT, Vaughan A, Temperton NJ, Wood JL, Cunningham AA, Suu-Ire R, Weiss RA, Fooks AR.

Virology. 2010 Dec 20;408(2):183-9. doi: 10.1016/j.virol.2010.09.014. Epub 2010 Oct 15.

45.

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A.

J Clin Invest. 2010 May;120(5):1663-73. doi: 10.1172/JCI41902. Epub 2010 Apr 12.

46.
47.

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.

Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B.

Vaccine. 2009 Oct 9;27(43):5998-6003. doi: 10.1016/j.vaccine.2009.07.079. Epub 2009 Aug 7.

PMID:
19665606
48.

Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1.

Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, Gellini M, Alberini I, Pittiglio E, Donatelli I, Temperton NJ, Cianfriglia M.

Antiviral Res. 2009 Sep;83(3):238-44. doi: 10.1016/j.antiviral.2009.05.005. Epub 2009 May 27.

PMID:
19481117
49.

Society of General Microbiology--2009 spring meeting.

Temperton N.

IDrugs. 2009 May;12(5):294-6. No abstract available.

PMID:
19431093
50.

Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses.

Oh S, Selleck P, Temperton NJ, Chan PK, Capecchi B, Manavis J, Higgins G, Burrell CJ, Kok T.

J Virol Methods. 2009 May;157(2):161-7. doi: 10.1016/j.jviromet.2008.12.016. Epub 2009 Jan 17.

PMID:
19152810

Supplemental Content

Loading ...
Support Center